



Technetium Tc 99m Red Blood Cells

Revised: March 17, 2021.

Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of technetium Tc 99m red blood cells as a diagnostic agent. A US Nuclear Regulatory Commission subcommittee has recommended that nursing be discontinued for 24 hours after administration of all technetium Tc 99m diagnostic products to simplify guidance recommendations, although this time interval may be longer than necessary.[1] The International Commission on Radiological Protection recommend that breastfeeding should be interrupted temporarily after administration of *in vivo* labeled red blood cells but need not be interrupted after administration of *in vitro* labeled red blood cells (see table).[2] To follow the principle of keeping exposure "as low as reasonably achievable", some experts recommend nursing the infant just before administration of the radiopharmaceutical and interrupting breastfeeding for 6 hours after the dose, then expressing the milk completely once and discarding it. During the period of interruption, the breasts should be emptied regularly and completely. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[3-5] The milk that is pumped by the mother during the time of breastfeeding interruption can either be discarded or stored refrigerated and given to the infant after 10 physical half-lives, or about 60 hours, have elapsed. Mothers need not refrain from close contact with their infants after usual clinical doses.[6]

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level, she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[7]

For nursing mothers who work with Tc 99m substances in their workplace, there is no need to take any precautions other than those appropriate for general radiation protection.[8]

Labeling Method	Dose	Duration of Interruption
in vivo	740 MBq (20 mCi)	6 to 12 hours[9]
in vitro	1000 MBq (30 mCi)	None required[2,9]

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Drug Levels

Tc 99m is a gamma emitter with a principal photon energy of 140 keV and a physical half-life of 6.04 hours.[1] The effective half-life of technetium Tc 99m red blood cells in vivo is 6.7 hours and 0.0057% of an administered dose is excreted into breastmilk.[10]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Dilsizian V, Metter D, Palestro C, et al. Advisory Committee on Medical Uses of Isotopes (ACMUI) Subcommittee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material. Final report submitted: January 31, 2019. Available at: <https://www.nrc.gov/docs/ML1903/ML19038A498.pdf>
2. Mattsson S, Johansson L, Leide Svegborn S, et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. ICRP Publication 128. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP. 2015;44(2 Suppl):319–21. PubMed PMID: 26069086.
3. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: Data, quantitative analysis and recommendations. Nucl Med Commun. 1989;10:15–27. PubMed PMID: 2645546.
4. Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St Louis Mosby-Year Book, Inc 1995:1380-1.
5. ARSAC notes for guidance: Good clinical practice in nuclear medicine. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2020. Available at: <https://www.gov.uk/government/publications/arsac-notes-for-guidance>
6. Mountford PJ, O'Doherty MJ. Exposure of critical groups to nuclear medicine patients. Appl Radiat Isot. 1999;50:89–111. PubMed PMID: 10028630.
7. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863–73. PubMed PMID: 10809203.
8. Almén A, Mattsson S. Radiological protection of foetuses and breast-fed children of occupationally exposed women in nuclear medicine - Challenges for hospitals. Phys Med. 2017;43:172–7. PubMed PMID: 28882410.
9. Mitchell KB, Fleming MM, Anderson PO, et al. ABM Clinical Protocol #30: Radiology and nuclear medicine studies in lactating women. Breastfeed Med. 2019;14:290–4. PubMed PMID: 31107104.
10. Leide-Svegborn S, Ahlgren L, Johansson L, et al. Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption. Eur J Nucl Med Mol Imaging. 2016;43:808–21. PubMed PMID: 26732471.

Substance Identification

Substance Name

Technetium Tc 99m Red Blood Cells

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Technetium Compounds

Diagnostic Agents